DOUGLAS B. CINES, M.D.; PETER A CASSILETH, M.D.; JOSEPH E. KISS, M.D.
Platelet-associated IgG was markedly elevated in three patients with myelodysplasia and severe thrombocytopenia that had become refractory to platelet transfusions. The patients were treated with danazol because of its efficacy in treating immune thrombocytopenic purpura where platelet destruction is primarily mediated by IgG autoantibodies. After danazol therapy, the platelet counts of each patient rose and clinical bleeding stopped, and a decline in hemolysis was seen in two patients. Danazol probably impeded the peripheral clearance of cells by macrophages; however, a beneficial effect of danazol on hematopoiesis cannot be excluded.
Learn more about subscription options.
Register Now for a free account.
CINES DB, CASSILETH PA, KISS JE. Danazol Therapy in Myelodysplasia. Ann Intern Med. 1985;103:58-60. doi: 10.7326/0003-4819-103-1-58
Download citation file:
Published: Ann Intern Med. 1985;103(1):58-60.
Coagulopathies, Hematology/Oncology, Platelet Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only